Science AI Journal
Medicine · Research topic

Open research questions in Treatment of Major Depression

127 unresolved questions extracted from the limitations and future-work sections of 1,584 Treatment of Major Depression papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • While our findings provide preliminary support for right amygdala-targeted TIS in MDD, the neuroimaging literature on amygdala lateralization remains inconclusive.

    Exploring the feasibility, safety and preliminary clinical effects of amygdala-targeted temporal interference stimulation for major depressive disorder: a pilot study · 2026 · DOI

  • BACKGROUND Aripiprazole can be used as an adjunctive treatment for depression, however, the drug-drug interactions (DDI) and initial dosage of aripiprazole in depressed patients remains unclear.

    Effects of paroxetine on aripiprazole and individualized administration in depressed patients based on model-informed precision dosing · 2026 · DOI

  • Therefore, it remains unclear whether perioperative esketamine is more effective in patients with pre- existing depressive symptoms, diagnosed mood disorders, or no baseline mood disturbance. The potential influence of concomitant psychotropic medication use on postoperative depressive symptom outcomes also could not be evaluated.

    Efficacy and safety of perioperative esketamine for postoperative depressive symptoms in breast cancer patients: a meta-analysis · 2026 · DOI

  • However, SERT occupancy influences serotonergic activity only indirectly via its effects on extracellular serotonin concentrations, and the relationship between these two variables is poorly characterized.

    The relationship between serotonin transporter occupancy and extracellular serotonin concentration is hyperbolic, not linear: implications for safely tapering antidepressants · 2026 · DOI

  • Beyond the canonical neuron-centric NMDAR inhibition hypothesis, brain opioid system and glia-mediated processes are increasingly implicated in ketamines antidepressant efficacy, yet their precise contributions remain poorly understood.

    Astrocytic μ-δ opioid receptor heterodimers mediate the antidepressant effects of ketamine's metabolite · 2026 · DOI

  • Regardless of the acknowledgement of SSRI discontinuation syndrome in literature, these brief electrical sensations experienced during withdrawal are still not understood well.

    Brain Zaps during Selective Serotonin Reuptake Inhibitor Withdrawal: An Overlooked Phenomenon in Psychiatry · 2026 · DOI

  •  In this study we attempted to find the effect of drug therapy and psychodynamic therapy for depression patients. www.wjpmr.com │ Vol 12, Issue 6, 2026. │ ISO 9001:2015 Certified Journal │ 211 Abinaya et al. World Journal of Pharmaceutical and Medical Research   The significance of this analysis lies in its cross- sectional design, as very few studies have explored depression and its therapies using this approach. In our study we have tried to establish the difference in the therapies and the severity of depression based on the therapy, but we could not say which therapy is effective, as we did not have baseline data for comparing the effect.  This is a real-time study, but in this study we did not concentrate specifically on a particular drug and whether the patients are undergoing regular or irregular therapy and relapse of the condition.  The data was taken only once, and based upon the duration and type of therapy, we have established our conclusions, which are applicable the particular population and time period on which the study was conducted, and these conclusions might not be considered for other studies. to CONCLUSION From this study we report that both drug therapy and drug therapy with counseling for depression show similar effects, and there is no significant difference between the two therapies. Depending upon the duration of therapies, patients undergoing drug therapy and counselling for a period of more than 3 months and less than a year are maintained in mild and moderate stages of depression; thus, the combined therapy is effective within 1 year of therapy. The findings suggest that combined therapy helps maintain mild depressive symptoms during the first year of treatment. However, long-term improvement requires further investigation due to irregular adherence in some patients. In patients undergoing both drug therapy and counselling, most were in the mild stage of depression; thus, patients' response to combined therapy is greater compared to drug therapy alone, but depending upon the patient’s condition and requirements, the type of therapy should be planned and decided. By this we conclude that the therapies show effects when given together. ACKNOWLEDGEMENT The authors are grateful to everyone who took part in this study, and also expressed their gratitude to all of the Academic heads who gave their consent for the study to be conducted. The authors extended their sincere gratitude to the principal and staff of JKKN College of Pharmacy for their support.

    A COMPARATIVE STUDY ON PSYCHODYNAMIC AND DRUG THERAPY AMONG UNIPOLAR DEPRESSIVE PATIENTS: A CROSS-SECTIONAL STUDY · 2026 · DOI

  • This study has several limitations. First, the analysis was restricted to older adults experiencing polypharmacy. As such, the findings may not be generalisable to all older individuals. However, polypharmacy is highly prevalent in this population, meaning the results remain clinically relevant for a substantial proportion of older adults. Centenarians, prisoners and individuals treated exclusively in private care were excluded. Consequently, outcomes among these groups may not be fully captured. In addition, the defined emergency hospital admission was counted on the same date of emergency department visits and hospital admissions. As a result, we excluded patients who stayed in the emergency department for more than 2 days, even if their stay fell within the 24-h time frame before admission. Although this study used data from Vision and EMIS-Optum, our findings may not be fully generalisable to populations captured by other EHR systems or to healthcare settings outside England. Validation in other data-sets, including international cohorts, is warranted. As with all observational studies, randomisation was not possible. Systematic differences may exist in the clinical conditions and underlying indications for antidepressant use between exposure groups. As such, the observed associations may partly reflect reverse causality, whereby the conditions for which antidepressants are prescribed themselves increase the risk of hospital admission. Withdrawal bias may have underestimated long-term maintenance risk, as treatment-tolerant individuals were more likely to continue therapy, creating a healthy survivor effect. Finally, missing data on prescription duration and medication adherence may have resulted in misclassification of antidepressant exposure phases. Importantly, we were unable to identify tapering regimens, as our data do not contain information on stepwise dose reductions or clinical intentions such as tapering or withdrawal. Tapering may therefore appear as prescriptions with dose changes or brief gaps, which may be classified as current use or recent use in our exposure definitions.

    Association between phases of antidepressant treatment and hospital admission for older adults in English primary care: matched case–control study · 2026 · DOI

  • IMPLICATIONS/CONCLUSIONS: Although the primary endpoint was not met in the efficacy population, which included participants with mild depression, statistically significant improvements with navacaprant on depressive symptoms including anhedonia in the moderate-to-severe MDD subgroup, along with a favorable safety profile, support further study of navacaprant for the treatment of MDD.

    Navacaprant, a Novel and Highly Selective Kappa Opioid Receptor Antagonist, in Adults With Major Depressive Disorder · 2025 · DOI

  • BACKGROUND: Electroconvulsive therapy (ECT) and subanesthetic intravenous ketamine are both currently used for treatment-resistant major depression, but the comparative effectiveness of the two treatments remains uncertain.

    Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression · 2023 · DOI

  • This review also highlights data for MDD clinical outcomes for which gaps in the literature have been identified, including the effects of antidepressants on functional outcomes, sleep disturbances, emotional and cognitive blunting, anxiety, and residual symptoms of depression.

    Considerations when selecting an antidepressant: a narrative review for primary care providers treating adults with depression · 2023 · DOI

  • Relatively little is known about the effects of selective serotonin re-uptake inhibitors (SSRI) on individuals exposed to differential dietary regimens, like caloric restriction (CR).

    Additive Antidepressant Effects of Combined Administration of Ecitalopram and Caloric Restriction in LPS-Induced Neonatal Model of Depression in Rats · 2020 · DOI

  • PURPOSE: We conducted a comprehensive meta-analysis of the comparison of tranylcypromine (TCP) and tricyclic antidepressants (TCAs) in the treatment of depression because such work is lacking in medical scientific literature.

    Efficacy and Adverse Effects of Tranylcypromine and Tricyclic Antidepressants in the Treatment of Depression · 2019 · DOI

  • To further advance the field and to ultimately realize effective and clinically feasible pharmacological preventive interventions for PTSD, reliable risk identification of PTSD, acceptability of preventive interventions, and implementation strategies should be investigated.

    Pharmacological Prevention of PTSD: Current Evidence for Clinical Practice · 2019 · DOI

  • ConclusionsFindings from this review indicate potential for the use of culturally adapted behavioural interventions to target depression in Indigenous populations; however, current evidence is insufficient to confirm their effectiveness.

    Evaluation of existing experimental evidence for treatment of depression in indigenous populations: A systematic review · 2018 · DOI

  • Furthermore, additive and synergistic effects of CRT with other treatment approaches should be examined and compared to create multimodal and even personalized intervention programs.

    Cognitive Impairment Along the Course of Depression: Non-Pharmacological Treatment Options · 2018 · DOI

  • Postulated action of ketamine causes a rapid resolution of depressive symptoms raised hopes to accelerate therapeutic effect of ECT in patients with severe depression, but studies provide contradictory data pointing to brevity of the observed effect.

    The use of ketamine in electroconvulsive therapy · 2015 · DOI

  • The aim of this work on one hand is to make psychiatrists aware that the role of anaesthesiologist at ECT is not limited to anaesthetise a patient and provide muscle relaxation, and, on the other hand, to make anaesthesiologists aware that drugs they use have a significant effect on seizure parameters and indirectly on the effectiveness of ECT.

    The use of ketamine in electroconvulsive therapy · 2015 · DOI

  • CONCLUSION: Clearly larger well designed placebo-controlled studies with longer follow-up accompanied by evaluations of tolerance/dependence are warranted before psychostimulants can be recommended in routine clinical practice for the treatment of MDD.

    Psychostimulants in moderate to severe affective disorder: A systematic review of randomized controlled trials · 2013 · DOI

  • Compared to published Latino proportions of non-retention (32-53%) and previous studies at our clinic with similar samples and medications (36-46%), Motivational pharmacotherapy appears to improve Latino retention in antidepressant therapy and should be investigated further in controlled designs.

    Impact of Motivational Pharmacotherapy on Treatment Retention Among Depressed Latinos · 2013 · DOI

  • OBJECTIVE: Although conflicting results have been obtained regarding P300 amplitude and latency in major depressive patients, most studies have reported that major depressive patients have smaller P300 amplitudes and longer latencies than healthy people.

    Event Related Potentials in Major Depressive Disorder: The Relationship between P300 and Treatment Response · 2012 · DOI

  • These approaches have not been directly compared; thus, our objectives are to compare outcomes for medication augmentation versus switching for patients with major depressive disorder in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) clinical trial.

    Treating Depression After Initial Treatment Failure · 2011 · DOI

  • Data for severe patients (MADRS> or =30) are scarce (only 1 RCT), indicating somewhat greater efficacy (response rate and MADRS reduction at week 8, but not CGI-S reduction) of escitalopram, but without compelling evidence of clinically relevant differences.

    Is Escitalopram Really Relevantly Superior to Citalopram in Treatment of Major Depressive Disorder? A Meta-analysis of Head-to-head Randomized Trials · 2010 · DOI

  • However, the influence of the serotonin and noradrenalin reuptake inhibitor (SNRI) venlafaxine and its metabolite O-desmethylvenlafaxine on the stimulated blood cell secretion of IFN-gamma has not been studied so far.

    IFN-γ Reduction by Tricyclic Antidepressants · 2010 · DOI

  • Promising findings from preclinical research on the effects of cocaine on serotonin lead to examination of selective serotonin reuptake inhibitors (SSRIs) as potential treatments for cocaine dependence with mixed results, possibly due to drug interactions or specifics of concomitant behavioral therapy.

    Citalopram Combined with Behavioral Therapy Reduces Cocaine Use: A Double-Blind, Placebo-Controlled Trial · 2007 · DOI

Most-cited papers in Treatment of Major Depression

Most recent work

Find a gap in your own Treatment of Major Depression sub-topic

This page shows what the Treatment of Major Depression literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Substance Abuse Treatment and Outcomes
989 open questions
Artificial Intelligence in Healthcare and Education
607 open questions
Attention Deficit Hyperactivity Disorder
448 open questions
Physical Activity and Health
436 open questions
Smoking Behavior and Cessation
402 open questions
Innovations in Medical Education
364 open questions
Dementia and Cognitive Impairment Research
363 open questions
HIV/AIDS Research and Interventions
342 open questions
127 open questions have been extracted from the limitations and future-work passages of 1,584 Treatment of Major Depression papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.